Skip to content

The value of nasal exhaled nitric oxide in the diagnosis and treatment of eosinophilic chronic sinusitis with nasal polyps

The value of nasal exhaled nitric oxide in the diagnosis and treatment of eosinophilic chronic sinusitis with nasal polyps

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000041580
Enrollment
Unknown
Registered
2020-12-31
Start date
2021-01-01
Completion date
Unknown
Last updated
2022-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic rhinosinusitis

Interventions

glucocorticoid group:Glucocorticoid Nasal spray
Saline group:Saline Nasal irrigation

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. A total of 96 patients with bilateral chronic sinusitis were selected (the diagnosis of chronic sinusitis was based on EPOS 2020 and CPOS diagnostic criteria). 2. Aged >= 18 and <= 75 years. 3. Subjects must had no history of other nose-related diseases. 4. Subjects are able to tolerate general anaesthetic surgery. 5. All subjects patient did not receive local or systemic glucocorticoid therapy for at least 4 weeks before surgery. 6. Volunteer to participate in the study and comply with the research requirements, agree to the operation, understand and follow-up plan, and correctly record scale scores, medication times, concomitant medication and adverse events.

Exclusion criteria

Exclusion criteria: 1. There are the following diseases: cystic fibrosis, congenital ciliary dyskinesia, nasal tumors or other obstructive injuries, large area of nasal bone hyperplasia, invasive or non-invasive fungal sinusitis; 2. There are serious metabolic, cardiovascular, immune, neurological, blood, digestive, cerebrovascular or respiratory diseases in clinic, or any disease that the researchers consider to interfere with the evaluation of the results of the study or affect the safety of the subjects; 3. Currently participating in other clinical studies or other clinical researchers within 30 days, or staff directly involved in the study; 4. Psychiatric history, antagonistic personality, bad motivation, suspicion or other emotional or intellectual problems may affect the effectiveness of informed participation in the study; 5. Pregnant or lactating women; 6. Drug allergy to glucocorticoid.

Design outcomes

Primary

MeasureTime frame
nasal symptom VAS score;Sinusitis Quality of Life Scale (SNOT-20);Sinus CT Lund-Mackey score;nasal endoscopy Lund-Kennedy score;Eosinophil count in nasal polyps;Absolute value of blood eosinophils;nasal exhaled nitric oxide;Fractional exhaled nitric oxide;

Countries

China

Contacts

Public ContactJing Ye

The First Affiliated Hospital of Nanchang University

yjholly@email.ncu.edu.cn+86 13979161109

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026